Hims & Hers (HIMS) Q2 earnings 2025

Shares of Hims & Hers Well being fell 9% in prolonged buying and selling on Monday after the telehealth firm reported second-quarter outcomes that missed Wall Avenue’s expectations for income.

Here is how the corporate did based mostly on common analysts’ estimates compiled by LSEG:

• Earnings per share: 17 cents adjusted vs. 15 cents anticipated
• Income: $544.8 million vs. $552 million anticipated

Income at Hims & Hers elevated 73% within the second quarter from $315.6 million throughout the identical interval final yr, in response to a launch. Hims & Hers reported a web earnings of $42.5 million, or 17 cents per share, in comparison with $13.3 million, or 6 cents per share, throughout the identical interval a yr earlier.

For its third quarter, Hims & Hers stated it anticipated to report income between $570 million and $590 million, whereas analysts had been anticipating $583 million. The corporate stated its adjusted earnings earlier than curiosity, taxes, depreciation and amortization, or EBITDA, for the quarter shall be between the vary of $60 million and $70 million. Analysts polled by StreetAccount had been anticipating $77.1 million.

Hims & Hers has confronted controversy in latest months over its continued sale of compounded GLP-1s, that are cheaper, unapproved variations of the blockbuster diabetes and weight reduction medicine. Compounded medicine may be mass-produced when brand-name remedies are in scarcity, however the U.S. Meals and Drug Administration introduced in February that ongoing provide points had been resolved.

Some telehealth corporations, together with Hims & Hers, have continued to supply the compounded drugs. It is authorized for sufferers to entry personalised doses of the knockoffs in distinctive circumstances, corresponding to if they’re allergic to an ingredient in a branded product, as an example. Hims & Hers has stated customers should be capable of entry personalised doses via its web site if clinically relevant. 

In June, Hims & Hers shares tumbled greater than 30% after a short-lived collaboration with Novo Nordisk fell aside. The drugmaker stated Hims & Hers “failed to stick to the legislation which prohibits mass gross sales of compounded medicine” underneath the “false guise” of personalization.

Hims & Hers reported adjusted EBITDA of $82 million for its second quarter, up from $39.3 million final yr and above the $73 million anticipated by StreetAccount.

Hims & Hers will host its quarterly name with buyers at 5 p.m. ET.

— CNBC’s Annika Kim Constantino contributed to this report.